When administered early in the onset of the cytokine storm phase, it is possible that rapamycin prevents progression to severe forms of COVID-19 through the down-regulation of SASPs, of the mTOR-NLRP3-IL-1β axis, of the IL-6 pathway, and of senescent T-cell counts [6]. The gene discussed is IL1B; the disease is COVID-19.